BioSpace News Archive

Satsuma Pharmaceuticals, Inc. (“Satsuma” or the “Company”) (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder) for the acute treatment of migraine, today announced the closing of the Company’s previously announced initial public offering of 5,500,000 shares of common stock at a public offering price of $15.00 per share,

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the promotion of Quentin Blackford to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer.

SCAN Health Plan®, one of the nation’s largest not-for-profit Medicare Advantage health plans, today announced the addition of CareMore Health to its provider network in Los Angeles, Orange and San Bernardino counties, effective Aug. 1, 2019.

Hope Orthopedics of Oregon announced the addition of Primary Care Sports Medicine physician, Dr. Alana Ryan to their Salem, Oregon clinic, located at 1600 State Street.

Riverain Technologies, a leading provider of clinical artificial intelligence software used to efficiently detect lung disease at its earliest stages, has received a $15 million growth investment led by Ping An Global Voyager Fund.

Senzer Pharmaceuticals has been granted a CE Mark that certifies its inhaler as a medical device, allowing it to now be available for patients in Europe for the ‘safe and effective delivery of pharmaceutical cannabinoids.’

MBio Diagnostics, Inc., today announced two contracts to develop new tests for algae toxins. These tests will expand the offerings available on MBio’s existing platform, the HAB Toxin System.

GB Sciences, Inc. (OTCQB: GBLX), on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC.